|
Published by: Datamonitor
Published: Sep. 22, 2009 - 108 Pages
Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the cancer therapy brands market
- Related reports
- Upcoming related reports
- CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Antihormonal therapies by ATC class
- L2A3 - Luteinizing hormone-releasing hormone agonists
- L2B1 - Anti-estrogens
- L2B2 - Anti-androgens
- L2B3 - Aromatase inhibitors
- L2B9 - Other hormone antagonists
- Cytotoxic therapies by ATC class
- L1A - Alkylating agents
- L1B - Antimetabolites
- L1C - Vinca alkaloids and other plant-derived products
- L1D - Antineoplastic antibiotics
- L1X2 - Platinum compounds
- L1X9 - All other antineoplastics
- Molecular targeted cancer therapies by ATC class
- L1D: Antineoplastic antibiotics
- L1X3: Antineoplastic monoclonal antibodies
- L1X4: Antineoplastic protein kinase inhibitors
- L1X9: All other antineoplastics
- L4A0: Immunosuppressive agents
- Countries and regions included in this report
- Cancer therapy brands included in this report
- Seven major market assessment
- Current and future market overview
- Sales of cancer therapies will exceed $70 billion in the seven major markets by 2018 as molecular targeted therapies drive most of the growth
- Higher growth in the five major European markets and Japan will reduce the dominance of the US cancer therapies market by 2018
- Molecular targeted therapies were the leading class of cancer therapy in 2008 and will significantly extend their dominance by 2018
- The Top 20 cancer therapy brands account for the majority of total cancer therapy by value despite accounting for the minority of sales by volume
- Roche's monoclonal antibody franchise dominated the cancer therapies market in 2008 and will continue to do so through to 2018
- US market assessment
- Current and future market overview
- A high rate of generic erosion will result in a decline in the size of the US cancer therapies market from 2014
- Japan market assessment
- Current and future market overview
- An underdeveloped generics market will facilitate high growth of cancer therapies sales in Japan
- Five major European market assessment
- Current and future market overview
- Sales of all three cancer therapy drug classes will grow between 2008 and 2018 in the five major European markets
- Rest of the World snapshot
- Current market assessment
- Rest of the World sales represent 20% of the global cancer therapies market
- Sales of cancer therapies in the BRIC countries are only marginally higher than in Canada despite a far higher patient population
- CHAPTER 3 BRAND DYNAMICS
- Overview of competitive landscape
- Seven major markets competitive landscape
- Top 20 cancer therapy brands in 2008
- Top 20 cancer therapy brands in 2018
- US competitive landscape
- Top 20 cancer therapy brands in 2008
- Top 20 cancer therapy brands in 2018
- Japan competitive landscape
- Top 20 cancer therapy brands in 2008
- Top 20 cancer therapy brands in 2018
- Five major European markets competitive landscape
- Top 20 cancer therapy brands in 2008
- Top 20 cancer therapy brands in 2018
- Leading antihormonal therapy brands
- Arimidex (anastrozole; AstraZeneca)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Lupron (leuprolide; Takeda/Abbott)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Leading cytotoxic therapy brands
- Taxotere (docetaxel; Sanofi-Aventis)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Eloxatin (oxaliplatin; Sanofi-Aventis)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Gemzar (gemcitabine; Eli Lilly)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Leading molecular targeted therapy brands
- Avastin (bevacizumab; Genentech/Roche/Chugai)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Rituxan (rituximab; Biogen Idec/Genentech/Roche/Chugai/ Zenyaku Kogyo)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Herceptin (trastuzumab; Genentech/Roche/Chugai)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Gleevec (imatinib; Novartis)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
- Drug profile
- SWOT analysis
- Brand forecast to 2018
- BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
- Other
- APPENDIX A - MARKET ASSUMPTIONS
- New product launches
- Patent expiries
- Data definitions, limitations and assumptions
- Standard units
- Derivation of sales forecasts and pricing trends
- Forecast methodology
- APPENDIX B
- Report methodology
- About Datamonitor
- About Datamonitor Healthcare
- About the oncology analysis team
- Disclaimer
- List of Tables
- Table 1: Definition of the cancer therapies market by ATC class, 2009
- Table 2: Drugs included in the Top 20 cancer therapy brands, 2008 and 2018
- Table 3: Sales and growth of cancer therapy drug classes in the seven major markets, 2008-2018
- Table 5: Comparison of cancer therapy drug class sales ($m) in the seven major markets and Rest of the World, 2008
- Table 6: Comparison of cancer therapy sales ($m) in the BRIC countries, Australia and Canada, 2008
- Table 7: Sales of the Top 20 cancer therapy brands in the seven major markets, 2008
- Table 8: Forecast sales of the Top 20 cancer therapy brands in 2018 in the seven major markets ($m), 2008-2018
- Table 9: Sales of the Top 20 cancer therapy brands in the US, 2008
- Table 10: Forecast sales of the Top 20 cancer therapy brands in 2018 in the US ($m), 2008-2018
- Table 11: Sales of the Top 20 cancer therapy brands in Japan, 2008
- Table 12: Forecast sales of the Top 20 cancer therapy brands in 2018 in Japan ($m), 2008-2018
- Table 13: Sales of the Top 20 cancer therapy brands in the five major EU markets, 2008
- Table 14: Forecast sales of the Top 20 cancer therapy brands in 2018 in the five major European markets ($m), 2008-2018
- Table 15: Arimidex (anastrozole) - drug profile, 2009
- Table 16: Impacting factors on the revenues of Arimidex, 2009-2018
- Table 17: Lupron (leuprolide) - drug profile, 2009
- Table 18: Impacting factors on the revenues of Lupron, 2009-2018
- Table 19: Taxotere - drug profile, 2009
- Table 20: Impacting factors on the revenues of Taxotere, 2009-2018
- Table 21: Eloxatin - drug profile, 2009
- Table 22: Impacting factors on the revenues of Eloxatin, 2009-2018
- Table 23: Gemzar - drug profile, 2009
- Table 24: Impacting factors on the revenues of Gemzar, 2009-2018
- Table 25: Avastin - drug profile, 2009
- Table 26: Impacting factors on the revenues of Avastin, 2009-2018
- Table 27: Rituxan - drug profile, 2009
- Table 28: Impacting factors on the revenues of Rituxan, 2009-2018
- Table 29: Herceptin - drug profile, 2009
- Table 30: Impacting factors on the revenues of Herceptin, 2009-2018
- Table 31: Gleevec - drug profile, 2009
- Table 32: Impacting factors on the revenues of Gleevec, 2009-2018
- Table 33: Erbitux - drug profile, 2009
- Table 34: Impacting factors on the revenues of Erbitux, 2009-2018
- Table 35: Datamonitor's forecast regional launch dates for new cancer therapies in the seven major markets, 2008-2018
- Table 36: Patent expiry dates for approved cancer therapy brands in the seven major markets, 2009-2018
- List of Figures
- Figure 1: Cancer therapy sales ($m) in the seven major markets, 2008-2018
- Table 4: Key events impacting the cancer therapies market, 2008-2018
- Figure 2: Cancer therapy sales ($m) by country in the seven major markets, 2008-2018
- Figure 3: Cancer therapy sales ($m) by class in the seven major markets, 2008-2018
- Figure 4: Sales (by value and volume) of the Top 20 cancer therapy brands versus sales of all other cancer therapies in the seven major markets, 2008 and 2018
- Figure 5: Sales and market share of the leading 10 cancer therapy brands in the seven major markets, 2008 and 2018
- Figure 6: Cancer therapy sales ($m) by class in the US, 2008-2018
- Figure 7: Cancer therapy sales ($m) by class in Japan, 2008-2018
- Figure 8: Cancer therapy sales ($m) by class in the five major European markets, 2008-2018
- Figure 9: Rest of the World versus seven major market sales split for sales of cancer therapies ($m), 2008
- Figure 10: Arimidex SWOT analysis, 2009
- Figure 11: Arimidex forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 12: Lupron SWOT analysis, 2009
- Figure 13: Lupron forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 14: Taxotere SWOT analysis, 2009
- Figure 15: Taxotere forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 16: Eloxatin SWOT analysis, 2009
- Figure 17: Eloxatin forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 18: Gemzar SWOT analysis, 2009
- Figure 19: Gemzar forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 20: Avastin SWOT analysis, 2009
- Figure 21: Avastin forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 22: Rituxan SWOT analysis, 2009
- Figure 23: Rituxan forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 24: Herceptin SWOT analysis, 2009
- Figure 25: Herceptin forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 26: Gleevec SWOT analysis, 2009
- Figure 27: Gleevec forecast sales ($m) by country in the seven major markets, 2008-2018
- Figure 28: Erbitux SWOT analysis, 2009
- Figure 29: Erbitux forecast sales ($m) by country in the seven major markets, 2008-2018
AbstractIntroduction
The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major pharmaceutical markets in 2008, growing at a CAGR of 17.4% between 2005 and 2008.
Scope
Forecast sales of the leading 20 cancer therapy brands in each of the seven major markets over the period 2008 to 2018Analysis and segmentation of the total cancer therapies market at various levels including drug class, country and brandComprehensive profiles and analysis for the key brands, including approval dates, patent expiries and all key events likely to impact salesSnapshot of the cancer therapies market in the rest of the worldHighlights
Datamonitor forecasts the cancer therapies market to reach sales of $70.4 billion by 2018. Sales growth over the forecast period will slow as some of the highest selling brands undergo patent expiry and several other brands will approach market saturation.
Molecular targeted therapies will continue to drive most of the growth of the cancer therapies market over the forecast period 20082018. This reflects this class's potential for increased uptake in existing indications, further indication expansions, relatively low incursion from generics and the modest impact of biosimilar market entrants.
Roche's monoclonal antibody franchise dominated the cancer therapies market in 2008 and will continue to do so through to 2018. Avastin was the top selling cancer therapy brand in 2008 and will remain the leading brand through to 2018. Expansion across a number of new tumor types and increasing uptake in new territories will drive this growth.
Reasons to Purchase
Quantify the performance of each of leading 20 cancer therapies in the seven major markets over the period 2008 to 2018Assess the changing key opportunities and threats both for currently marketed and pipeline cancer therapy brandsIdentify the leading brands in this market over the next 10 years and understand the key factors driving their success
Please note: this is delivered as a Zip file.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
